:max_bytes(150000):strip_icc():focal(749x0:751x2)/gpl-1-jabs-052226-1-010a064224da4f85bf4c6ea0952739c8.jpg)
new glp 1 GLP-1 Weight Loss Drugs May Reduce Chance of Cancer Progressing, Study Finds GLP-1 Pipeline Update: May 2026
Description
Gastric inhibitory polypeptide activates MAP kinase through the wortmanninsensitive and insensitive pathways
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
Six cost drivers explain it, none related to the drug itself
Among the various causes of diabetes, obesity is a major contributor and is characterized by an excess accumulation of adipose tissue
Leiter, M.C
Maximum Weight Loss Potential (Future) Amycretin Phase 1b/2a showed up to 24.3% weight loss at 36 weeks with no plateau, suggesting even greater loss with longer treatment
